Table 5 Risk factors for ICC in PS matched cohort.

From: Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B

 

Univariate analysis

Multivariate analysis

HR

95% CI

P-value

HR

95% CI

P-value

Main model

Tenofovir (ref: Entecavir)

0.92

0.28

2.99

0.890

0.94

0.29

3.07

0.914

Age, y/o

1.10

1.05

1.16

< 0.001

1.09

1.04

1.15

0.001

Male (ref: Female)

2.70

0.60

12.08

0.194

2.94

0.65

13.23

0.160

Liver Cirrhosis (ref: without)

6.27

1.40

28.01

0.016

3.59

0.78

16.42

0.100

DM (ref: without)

2.69

0.90

8.04

0.077

1.54

0.50

4.72

0.449

Covariates

Plateleta

0.996

0.988

1.004

0.297

1.004

0.996

1.012

0.365

AFPa

0.999

0.989

1.008

0.790

0.998

0.986

1.010

0.763

Albumina

0.60

0.29

1.24

0.167

0.80

0.36

1.77

0.585

Bilirubina

0.95

0.75

1.19

0.643

0.91

0.67

1.23

0.530

INRa

2.00

0.63

6.30

0.237

1.73

0.43

6.93

0.436

FIB-4a

1.14

0.93

1.39

0.223

1.12

0.88

1.42

0.353

APRIa

1.05

1.02

1.08

< 0.001

1.04

1.00

1.09

0.044

  1. PS propensity score, HR hazard ratio, CT confidence interval, DM diabetes mellitus, AFP alpha-fetoprotein, INR international normalized ratio, FIB-4 fibrosis index based on 4 factors, APRI AST to platelet ratio index.
  2. aAdjusted for tenofovir, sex, age, liver cirrhosis, DM.
Back to article page